TUCSON, Ariz., Dec. 30, 2025 (GLOBE NEWSWIRE) — Picard Medical, Inc. (NYSE American: PMI) (“Picard” or the “Company”), parent company of SynCardia Systems, LLC, maker of the world’s first total artificial heart approved by both the U.S. Food and Drug Administration (FDA) and Health Canada today announced that Patrick NJ Schnegelsberg, Chief Executive Officer of Picard Medical and SynCardia Systems, LLC, has been elected to the Board of Directors of the Arizona Bioindustry Association (AZBio), the state affiliate in Arizona of the Biotechnology Industry Organization (BIO), the preeminent national association for biotechnology companies His term serving on the board will extend through December 2028.Continue reading
Category Archives: AZBio News
Picard Medical Announces Up to $50 Million Senior Secured Debt Financing
TUCSON, Ariz., Dec. 24, 2025 (GLOBE NEWSWIRE) — Picard Medical, Inc. (NYSE American: PMI) (“Picard” or the “Company”), parent company of SynCardia Systems LLC, maker of the world’s first total artificial heart approved by both the U.S. FDA and Health Canada, today announced that it has entered into a definitive agreement for a private placement financing of up to $50.0 million aggregate principal amount of senior secured notes due 2028 together with warrants to purchase common stock of the Company. WestPark Capital Inc. served as Sole Placement Agent.Continue reading
Collaboration key to future of ASU Health, President Crow says
Government, health care and academic leaders gather for annual State of the Phoenix Bioscience Core in downtown Phoenix
Aqualung Therapeutics Receives FDA Clearance for Phase 2a Lung Fibrosis Study
Aqualung Therapeutics Receives FDA Clearance for Phase 2a Lung Fibrosis Study
Continue reading
OTEF Announces the 2025 Improving Health for Veterans Grantees
The State of Arizona is investing in the future of veteran health with a $150,000 appropriation to ASTO for FY26. Managed by the Opportunity Through Entrepreneurship Foundation (OTEF), these funds empower the AZAdvances initiative to bridge the gap between life science entrepreneurship and patient care. By accelerating health innovations and strengthening the local workforce, OTEF/AZAdvances and the Arizona Health Innovation Trust Fund (AHIT) are working to ensure a healthier future for all Arizonans.
The 2025-2026 AZAdvances Improving Health for Veterans were awarded to Life365, MiiHealth.AI, Regenesis Medical, and the Ndee Bikiyaa (The People’s Farm), White Mountain Apache Tribe.
Continue reading
Gilead and U.S. Government Enter Agreement to Lower Costs of Medicines for Americans
- Gilead and U.S. Government Enter Agreement to Lower Costs of Medicines for Americans
- Agreement addresses all requests by President Trump to reduce drug costs in the U.S., encourage global investment and protect American biopharma leadership
- Company reinforces commitment to U.S. manufacturing and American jobs
Genentech Announces Agreement With U.S. Government
- Agreement with the U.S. government addresses prescription drug costs and encourages other wealthy nations to reward biopharmaceutical innovation
- Influenza portfolio to be made available through TrumpRx.gov and through Genentech’s recently-launched direct-to-patient program
- Company commitment to U.S. manufacturing, infrastructure, and R&D reaffirmed, building on the recent $50 billion investment announcement and recent groundbreaking of new manufacturing facility in North Carolina
- Government exempts Genentech portfolio from tariffs, enabling Genentech’s continued investment and expansion of its manufacturing footprint in the U.S.
GSK enters agreement with U.S. government to lower drug prices and expand access to respiratory medicines for millions of Americans
- Voluntary agreement delivers on all four of President Trump’s requests and reduces the cost of medicines for Americans
- Includes products used to treat the more than 40 million patients in the U.S. who suffer from respiratory conditions such as asthma and COPD
- Builds on GSK’s decades-long commitment to make products accessible worldwide to those who need them
Amgen Takes Action with the U.S. Government to Lower the Cost of Medicines for American Patients
Underscores Long-Standing Commitment to Investing in Innovation and U.S. ManufacturingContinue reading